AstraZeneca gets EU backing for targeted breast cancer therapies
Send a link to a friend
[June 27, 2022]
AstraZeneca gets EU backing for
targeted breast cancer therapies
(Reuters) - AstraZeneca said on Monday two of its existing therapies
were recommended for treating patients with some forms of high-risk
breast cancers in the European Union, in a boost to the company's
oncology portfolio.
Lynparza, a cancer drug developed jointly with U.S.-based Merck, was
backed for standalone use or in combination with endocrine therapy in
adults with a form of genetically mutated early-stage breast cancer.
The drug, which has received a similar recommendation in the United
States in March, is a key asset for AstraZeneca. It was recommended in
patients with low-to-normal levels of a protein known as HER2 that is
the target of several new therapies.
![](http://archives.lincolndailynews.com/2015/May/02/images/ads/current/guzzardo_lda022609.png)
[to top of second column]
|
![](../images/062722PIX/health5.jpg)
The logo for AstraZeneca is seen outside its North America
headquarters in Wilmington, Delaware, U.S., March 22, 2021.
REUTERS/Rachel Wisniewski/File Photo
![](http://archives.lincolndailynews.com/2022/Jun/27/images/ads/current/heartland_lda_NOV2021.png) Enhertu, developed jointly with
Japan's Daiichi Sankyo, was the other drug that was endorsed by the
European Medicines Agency for treating an aggressive form of breast
cancer characterised by a high rate of HER2.
Enhertu is seen as a major growth driver for AstraZeneca, with some
analysts expecting peaks sales of $10 billion. The drug is also
expected to be cleared for patients with low levels of HER2 this
month after the recent success of a trial.
(Reporting by Amna Karimi in Bengaluru; Editing by Rashmi Aich and
Anil D'Silva)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |